All subscribers to ACOG UPDATE audio CDs will also have free access and ability to download the same program in MP3 format. They can also download a PDF file of the complete transcript with Pre- and Post-test Questions and a List of Supplementary Reading Materials.
Volume 43, Issue 5
Publication date: November 1, 2017
November 1, 2020
Maternal/Fetal Risks From Opioid Use Disorders: What You Need To Know
Tricia Wright, MD, MS (Moderator)
Associate Professor of Obstetrics, Gynecology, and Women’s Health; Clinical Associate Professor of Psychiatry, University of Hawaii John A. Burns School of Medicine, Honolulu, Hawaii
Alta J. DeRoo, MD
Associate Professor of Obstetrics and Gynecology, University of Virginia School of Medicine; Director of Obstetrics and Gynecology, Novant Health UVA Health System Culpeper Medical Center, Culpeper, Virginia
Mishka Terplan, MD, MPH
Professor of Obstetrics and Gynecology and Psychiatry, Virginia Commonwealth University, Richmond, Virginia
After completing this activity, the physician should be better able to:
Describe why medically assisted treatment with either methadone or buprenorphine rather than medical withdrawal remains the preferred treatment for pregnant women with opioid use disorders.
Provide nonjudgmental prenatal care for women with opioid use disorders, using person-first, nonstigmatizing language.
Counsel patients on minimizing neonatal abstinence syndrome (NAS) by focusing on modifiable risk factors, such as cigarette smoking, alcohol intake, and other substance use.
Organize a health care team for the management of labor and delivery.
Manage the “4th trimester” of pregnancy to minimize the risk of relapse and substance-exposed pregnancy.